Bristol-Myers Squibb Is A Great Buy, But These 5+% Yielding Bargains Are BetterSeeking Alpha • 11/28/23
Avidity's stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone paymentsMarket Watch • 11/28/23
Bristol-Myers Squibb, 2seventy Bio Shares Fall as FDA Delays Decision on Cancer DrugInvestopedia • 11/20/23
Bristol-Meyers Squibb shares fall as FDA delays blood cancer therapy decisionProactive Investors • 11/20/23
Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatmentMarket Watch • 11/20/23
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple MyelomaBusiness Wire • 11/20/23